Loading organizations...
Key people at AmplifiDx.
Based in Boston, Massachusetts, AmplifiDx develops molecular diagnostic assays and rapid point-of-care testing platforms for infectious diseases. The company's proprietary DX 100 Platform utilizes nucleic acid amplification technologies to deliver test results for up to ten analytes, including COVID-19 and influenza, in twenty to thirty minutes. These diagnostic tools are designed for deployment in physician offices, remote clinics, and women's health facilities to provide accessible testing for underserved patient populations. AmplifiDx has secured approximately $5 million in total non-dilutive funding to date, including a $1.38 million grant from the National Institutes of Health through its RADx program. The enterprise is backed by venture capital firm Avestria Ventures and maintains strategic development partnerships with FreeMind Group and Veranex. AmplifiDx was founded in 2020 by a team of industry veterans and is currently led by Chief Executive Officer Nancy Shoenbrunner.
Key people at AmplifiDx.
AmplifiDx is a molecular diagnostics company developing the DX-100™ platform, a compact, affordable point-of-care (POC) testing system that delivers fast, accurate results in under 30 minutes using advanced nucleic acid amplification technology (NAAT).[1][2][3][4] It targets infectious diseases like STIs, respiratory illnesses (COVID-19, influenza A/B, RSV), and women's health conditions, serving healthcare professionals, clinics, and underserved communities with lab-quality multiplex testing from a single sample—such as a nasal swab—to enable test-to-treat decisions and reduce disease spread.[1][3][4][6] The platform emphasizes low hands-on time (less than one minute), multiplexing up to 10 targets, and scalability for global access, addressing gaps in rapid, cost-effective diagnostics.[1][2][6]
Growth momentum includes multiple NIH RADx grants totaling over $2.3 million since 2021, including $1.38M in 2023 for DX-100 and RespiFast Assay development, plus $954K for COVID-19 enhancements, de-risking the technology via non-dilutive funding and partnerships like Veranex for rapid prototyping.[2][3][4][5][7]
AmplifiDx was founded in 2020 amid the COVID-19 pandemic by industry veterans, including CEO Nancy Schoenbrunner, who brings decades of experience from Roche Diagnostics—leading projects like the cobas® Liat® POC system, cobas® EGFR liquid biopsy, and cobas® 6800/8800 lab platforms.[4][6] The idea emerged from Schoenbrunner's expertise in molecular diagnostics and POC solutions, combined with a team focused on scaling manufacturable, affordable tech to combat infectious diseases globally, prioritizing "voice of manufacturing" to avoid past scalability failures.[6]
Early traction came swiftly: non-dilutive funding from FreeMind Group since 2021, NIH RADx contracts for COVID-19 tech validation, and Veranex partnership yielding a proof-of-concept DX-100 prototype in under three months.[2][5][7] These milestones validated the isothermal detection and lamp amplification approach, propelling menu expansion into syndromic panels.[4][5][6]
AmplifiDx rides the POC molecular diagnostics wave, accelerated by pandemics exposing delays in lab-based testing, with demand surging for rapid, decentralized solutions in respiratory/STI outbreaks and community health—the fastest-growing diagnostics segment.[3][4][6] Timing aligns with post-COVID infrastructure (e.g., NIH RADx network) and trends like syndromic panels for efficient triage, countering market forces like high POC costs and lab backlogs.[2][4][7]
It influences the ecosystem by de-risking via grants, fostering partnerships (Veranex, FreeMind, Avestria Ventures), and prioritizing manufacturability to enable broader adoption in clinics and low-resource settings, potentially reducing healthcare costs and loss-to-follow-up.[2][3][5][6]
AmplifiDx is poised for menu expansion into more infectious diseases, women's health, and early detection assays, leveraging NIH momentum and prototypes toward commercialization.[1][4][5] Trends like multiplex POC demand, AI-enhanced optics, and global health preparedness (e.g., next pandemics) will shape growth, with manufacturing focus enabling penetration into community health markets.[6]
Its influence may evolve from grant-funded innovator to scalable provider of "lab-quality everywhere," amplifying impact through affordable tech—if regulatory clearances (noted as pending) and partnerships materialize—ultimately transforming infectious disease management as envisioned from its pandemic origins.[1][4][6]
